According to Zhitong Finance App, Bishengyuan (00926.HK) announced that the company expects to record a significant fair value loss of approximately RMB 16.3 million for its investment in ERX Pharmaceuticals Inc. (a clinical-stage biomedical company incorporated under Delaware law). This fair value loss was mainly due to recent changes in the US capital market environment. Investors' capital clearly favors technology sectors such as artificial intelligence (AI), leading to a slump in traditional drug development and clinical research financing activities, leaving ERX lacking external funding for new drug development activities. This financing difficulty put pressure on ERX's short-term valuation, leading to a sharp decline in ERX's valuation.

According to Zhitong Finance App, Bishengyuan (00926.HK) announced that the company expects to record a significant fair value loss of approximately RMB 16.3 million for its investment in ERX Pharmaceuticals Inc. (a clinical-stage biomedical company incorporated under Delaware law). This fair value loss was mainly due to recent changes in the US capital market environment. Investors' capital clearly favors technology sectors such as artificial intelligence (AI), leading to a slump in traditional drug development and clinical research financing activities, leaving ERX lacking external funding for new drug development activities. This financing difficulty put pressure on ERX's short-term valuation, leading to a sharp decline in ERX's valuation.